Sunday 18 October 2026
Export VTVT’s income statement to Excel — free account
vTv Therapeutics Inc.
VTVT Healthcare Biotechnology
In the quarter to June 2026, revenue grew 409,222.2%, EPS fell 14.1% and free cash flow fell 124.6%, each against the same quarter a year earlier.
26.54
1.05
−3.81%
Follow VTVT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (11.74%) | 4.56% | (68.52%) | (53.07%) |
+8 more TTM periods Free account |
|
| (8.34%) | 3.44% | (42.09%) | (32.90%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(5.90%) | 2.45% | (32.40%) | (26.28%) | |
Average Days of Receivables |
— | 0.00 | — | — | |
Free Cash Flow per Share |
(1.35) | (0.84) | (3.00) | (2.59) | |
Free Cash Flow |
(16.76) | (10.41) | (25.25) | (20.83) | |
| Other line items | |||||
Cash ROIC |
(10.14%) | (5.54%) | (16.47%) | (12.32%) | |
Accounts Receivable Turnover |
— | 0.00 | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.14 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 63.41% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 41.92% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 11.49% | 0.00% | 0.00% | |
Interest Coverage |
— | — | (1,562.29) | (1,242.29) | |
Operating CF/Net income |
3.52 | (4.62) | 0.94 | 0.89 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 2.57 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 3.05 | 0.00 | 0.00 | |
Operating CF per Share |
(1.35) | (0.84) | (3.00) | (2.59) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | — | — |
Columns are period end dates